Sign in

    Elliot Wilbur

    Senior Research Analyst at Raymond James

    Elliot Wilbur is a Senior Research Analyst at Raymond James specializing in the healthcare sector, with a focus on biotechnology, pharmaceuticals, and life sciences companies, and he actively covers a portfolio of 48 stocks including firms such as ANI Pharmaceuticals. His performance as tracked on platforms like TipRanks shows a success rate of 37.03% and he holds a 0.14-star rating based on actual investment returns. Wilbur has an established career at Raymond James, where he has led healthcare research for multiple years and regularly engages with executive teams at covered firms. He holds professional licenses required for equity research analysis and is FINRA-registered, reflecting his industry credentials.

    Elliot Wilbur's questions to Adicet Bio (ACET) leadership

    Elliot Wilbur's questions to Adicet Bio (ACET) leadership • Q3 2018

    Question

    Elliot Wilbur of Raymond James inquired about the mechanics of failure-to-supply contract clauses, specifically asking if the company has open-ended liability in cases of significant price increases, and also requested the depreciation and amortization figures for the quarter.

    Answer

    COO Walt Kaczmarek and Chief Legal Officer Steve Rogers explained that liability is generally not open-ended and is tied to customer forecasts, with negotiated caps and restrictions varying by contract. After a brief search, President and CEO Bill Kennally provided an estimated quarterly depreciation and amortization figure of approximately $8 million.

    Ask Fintool Equity Research AI